Wuxi Clinical Development Services (Shanghai) Co., Ltd.

Primary objective: To evaluate the effect of paltusotine vs. placebo on IGF-1 response; Key secondary objectives: To evaluate the effect of paltusotine vs. placebo on IGF-1 levels; Secondary objectives: 1) To evaluate the effect of paltusotine vs. placebo on IGF-1 response; 2) To evaluate the effect of paltusotine vs. placebo on GH response; 3) To evaluate the effect of paltusotine vs. placebo on acromegaly symptoms;

Primary objective: To evaluate the pharmacokinetics (PK) of single and multiple doses of paltusotine in the Chinese population; Secondary objective: To evaluate the safety of paltusotine in the Chinese population.

Primary objective: To evaluate and compare investigator-assessed progression-free survival (PFS) of tazemetostat+R2 versus placebo+R2 in R/R FL patients with EZH2 WT and EZH2 MT, respectively. Secondary objectives: To evaluate and compare complete response rate (CRR), objective response rate (ORR), overall survival (OS), duration of response (DOR), duration of complete response (DOCR), disease control rate (DCR), safety, and tolerability in the R/R FL patient population with EZH2 WT and EZH2 MT, and in all R/R FL patients (regardless of mutation status); to evaluate and compare PFS assessed by investigator in the R/R FL population (regardless of mutation status), and PFS assessed by blinded independent review committee (IRC) in the R/R FL patient population with EZH2 WT and EZH2 MT, and in all R/R FL patients (regardless of mutation status); to evaluate and compare PFS assessed by investigator in the R/R FL patient population with EZH2 WT and EZH2 MT, and in all R/R Population PK parameters, including the exposure-response relationship of tazemetostat when co-administered with R2, and health-related quality of life (QoL) measured by the EQ-5D-5L tool and FACT-Lym were assessed in FL patients regardless of mutation status.